Cost-effectiveness of prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention

Int J Cardiol. 2018 Jan 15:251:32. doi: 10.1016/j.ijcard.2017.09.155.

Authors

Michael Spartalis¹, Eleni Tzatzaki², Nikolaos I Nikiteas³, Eleftherios Spartalis³

Affiliations

¹ Division of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece. Electronic address: msparta@med.uoa.gr.
² Division of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.
³ Laboratory of Experimental Surgery and Surgical Research, University of Athens, Medical School, Athens, Greece.

PMID: 29197452
DOI: 10.1016/j.ijcard.2017.09.155

No abstract available

Keywords: Acute coronary syndrome; Clopidogrel; Cost-effectiveness; Prasugrel.

Publication types

Letter
Comment

MeSH terms

Acute Coronary Syndrome*
Clopidogrel
Cost-Benefit Analysis
Humans
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
Prasugrel Hydrochloride*
Ticlopidine / analogs & derivatives
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Clopidogrel
Prasugrel Hydrochloride
Ticlopidine